Vallejo E

Language: Spanish
References: 14
Page: 160-162
PDF size: 86.76 Kb.

ABSTRACT

Evaluation of myocardial viability with the aid of radionuclides, is a technique that offers reliable, reproducible information, with an attractive cost-benefit relationship, in the study of the myocardial viability, integrating cardiac molecular, metabolic, and functional aspects. Nowadays, coronary risk stratification in post-myocardial infarction patients pretends to locate them as low-, intermediate, and high risk-subjects that can suffer cardiovascular complications in the very near future. Low-risk patients are characterized by a cardiac-related mortality below 1%, whereas high-risk mortality is greater than 3%. Because of clinical complications following a myocardial infarction are observed during the first month of evolution, clinical guidelines suggest to evaluate the cardiovascular risk before hospital discharge.

REFERENCES

1. Sawada SG: Positron emission tomography for assessment of viability. Curr Opin Cardiol 2006; 21: 464-468.

2. Chouraqui P, Livschitz S, Baron J, et al: The assessment of infarct size in postmyocardial infarction patients undergoing thallium-201 tomographic imaging is improved using attenuation correction. Clin Nucl Med 2004; 29: 352-357.

3. Patel RAG, Beller GA: Prognostic role of single-photon emission computed tomography (SPECT) imaging in myocardial viability. Curr Opin Cardiol 2006; 21: 457-463.

4. Pitt M, Dutka D, Pagano D, Camici P, Bonser R: The natural history of myocardium awaiting revascularization in patients with impaired left ventricular function. Eur Heart J 2004: 500-507.

5. Candell-Riera J, Castell-Conesa J, Jurado-López JA, López de Sá E, Nuño de la Rosa JA, et al: Guías de actuación clínica de la Sociedad Española de Cardiología. Cardiología Nuclear: Bases y aplicaciones clínicas. Rev Esp Cardiol 1999; 52: 957-89.

6. Gould KL: Assessing Myocardial Viability. En: Coronary Artery Stenosis and reversing atherosclerosis. 2ª Ed. New York. Oxford University Press, 1999, p. 329-357.

7. Entok E, Cavusoglu Y, Kaya E, Vardareli E, Timuralp B: Detection of hibernate myocardium by 99mTc sestamibi gated SPECT during low-dose dobutamine infusion plus nitrate in patients with first acute myocardial infarction. Nucl Med Commun 2005; 26: 765-772.

8. Arrighi JA, Dilsizian V: Assessment of myocardial viability by radionuclide and echocardiography techniques: is it simply a sensitivity and specificity issue. Curr Opin Cardiol 1006; 21: 450-456.

9. Levine MG, McGill CC, Ahlberg AW: Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. Am J Cardiol 1999; 83: 1-5.

10. DiCarli M: Assessment of myocardial viability after myocardial infarction. J Nucl Cardiol 2002; 9: 229-35.

11. Sisson JC, Shapiro B, Myers L, Mallette S, Mangner TJ, Wieland DM, et al: Metaiodobenzylguanidina to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-36.

12. Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH, et al: Regional sympathethic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol 1989; 14: 1519-26.

13. Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G, et al: Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000; 101: 2579-2585.

14. Ypenburg C, Schalij MJ, Bleeker GB, et al: Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. J Nucl Med 2006; 47: 1565-1570.